Jubilee Brown, MD, discusses the clinical implications of the phase 3 PRIMA trial in advanced ovarian cancer.
Jubilee Brown, MD, professor, director, Gynecologic Oncology, Levine Cancer Institute, Atrium Health, discusses the clinical implications of the phase 3 PRIMA trial (NCT02655016) in advanced ovarian cancer.
The PRIMA trial evaluated the PARP inhibitor niraparib (Zejula) vs placebo as frontline maintenance therapy in patients with newly diagnosed advanced ovarian cancer who had a response to platinum-based chemotherapy. Ultimately, the results of the trial indicated that niraparib outperformed placebo in terms of progression-free survival irrespective of the presence or absence of homologous recombination deficiency (HRD).
The all-comer benefit observed informs clinical decisions, Brown explains. After frontline platinum-based chemotherapy, patients should be considered for treatment with niraparib independent of the presence or absence of germline or somatic BRCA mutations or HRD, Brown concludes.